Actinium Pharmaceuticals Inc (ATNM)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $46.85M
Last updated: Nov 17, 2026 at 4:10 PM ET
Actinium Pharmaceuticals Inc (ATNM) Statistics
Actinium Pharmaceuticals (ATNM) has a market cap of $46.85M and an enterprise value of $18.17M. Revenue grew 3788.89% over the last 12 months from the 12 months before. It holds $28.68M more cash than debt, 61.21% of its market cap.
Total Valuation
Enterprise value is 61.21% below the market cap, as cash exceeds debt.
| Market Cap | $46.85M |
|---|---|
| Enterprise Value | $18.17M |
| Latest price (Nov 17, 2026) | $1.33 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 16, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.2x and 1.7x.
| P/E Ratio | 4.0x |
|---|---|
| P/S Ratio | 1.2x |
| Forward P/S | 1.3x |
| P/B Ratio | 1.7x |
Enterprise Valuation
Counting debt and cash, the company is valued at 1.4x EBITDA.
| EV / Earnings | 1.7x |
|---|---|
| EV / Sales | 0.5x |
| EV / EBITDA | 1.4x |
Price Statistics
The stock is up 4.72% over 52 weeks and trades 2.31% above its 50-day average.
| Beta (1Y) | 0.83 |
|---|---|
| 52-Week Change | +4.72% |
| 1-Month Change | +0.76% |
| 3-Month Change | +17.70% |
| 6-Month Change | +15.65% |
| 5-Year Change | -81.15% |
| 10-Year Change | -94.81% |
| Total Return (1Y) | +4.72% |
| Total Return (3Y CAGR) | -33.33% |
| Total Return (5Y CAGR) | -29.71% |
| Return vs SPY (1Y) | -18.55% |
| Max Drawdown (1Y) | -55.70% |
| Max Drawdown (3Y) | -92.43% |
| Sharpe Ratio (1Y) | -0.10 |
| Correlation with SPY (1Y) | 0.16 |
| 50-Day Average | $1.30 |
| 200-Day Average | $1.13 |
| 52-Week Range | $0.73 to $1.72 |
| RSI (14 Days) | 46.1 |
| Average Volume (20 Days) | 245.76K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.00x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 4.00x |
|---|---|
| Quick Ratio | 4.00x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is 43.10% and return on assets is 32.64% over the last 12 months.
| Return on Equity (ROE) | 43.10% |
|---|---|
| Return on Assets (ROA) | 32.64% |
| ROA (5Y Average) | -46.97% |
| Asset Turnover | 0.79x |
Taxes
Income tax took 0.00% of pretax income over the last 12 months.
| Income Tax (TTM) | $0 |
|---|---|
| Effective Tax Rate | 0.00% |
Scores
ATNM has an Altman Z-Score of -10.95, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -10.95 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $35.00M over the last 12 months.
| Revenue | $35.00M |
|---|---|
| Revenue Growth (YoY) | +3788.89% |
| Gross Profit | $35.62M |
| Operating Income | $9.13M |
| Pretax Income | $10.60M |
| Net Income | $10.60M |
| Reported EPS (TTM) | $0.33 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 75.73% of the $32.47M in total assets.
| Cash and Equivalents | $28.68M |
|---|---|
| Total Debt | $0 |
| Net Cash | $28.68M |
| Net Cash Per Share | $0.91 |
| Working Capital | $22.12M |
| Shareholder Equity | $24.59M |
| Book Value Per Share | $0.78 |
| Total Assets | $32.47M |
| Total Liabilities | $7.88M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.35M of capital spending, operating cash flow left -$24.71M of free cash flow.
| Operating Cash Flow | -$23.36M |
|---|---|
| Capital Expenditures | $1.35M |
| Free Cash Flow | -$24.71M |
| FCF Per Share | -$0.79 |
| Depreciation and Amortization | $1.31M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 26.07%.
| Gross Margin | 101.76% |
|---|---|
| Operating Margin | 26.07% |
| Pretax Margin | 30.27% |
| Net Margin | 30.27% |
| FCF Margin | -70.61% |
Growth
Revenue fell 55.63% a year over 3 years.
| Revenue Growth (3Y CAGR) | -55.63% |
|---|---|
| Book Value Per Share Growth (2Y CAGR) | -56.32% |
| Tangible Book Per Share Growth (2Y CAGR) | -56.32% |
Dividends and Yields
ATNM does not pay a dividend. Its free cash flow yield is -59.10%.
| Earnings Yield | 25.00% |
|---|---|
| FCF Yield | -59.10% |
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-30 reverse split on Aug 11, 2020.
| Last Split Date | Aug 11, 2020 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:30 |
Peer Position
Against 4 similar companies, ATNM has the lowest P/S.
P/S RatioPeer median 124.6x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -100.00%
| P/S Ratio | 1.2x vs 124.6x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +3788.89% vs -100.00% median |
Analyst Forecast
Consensus estimates put revenue growth at 38788.89% a year over the next fiscal year.
| Revenue Growth Forecast (1Y CAGR) | +38788.89% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ATNM
What is ATNM's market cap?
Actinium Pharmaceuticals has a market cap of $46.85M. Its enterprise value, which adds debt and subtracts cash, is $18.17M.
What is ATNM's P/E ratio?
Actinium Pharmaceuticals has a trailing P/E ratio of 4.0x.
How many shares of ATNM are outstanding?
Actinium Pharmaceuticals has 31.44M shares outstanding. The count is up 0.79% from a year earlier.
Does ATNM pay a dividend?
No. Actinium Pharmaceuticals does not pay a dividend.
How much debt does ATNM have?
Actinium Pharmaceuticals has $0 of total debt and $28.68M of cash and equivalents, a net cash position of $28.68M.
ATNM pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors